Small randomized trials

Journal of Thoracic Oncology

Volumn 2, Issue 1, 2007, Pages 1-2

  Redman, Mary ^a,b   Crowley, John ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSTATIC AGENT;

CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL STUDY; CLINICAL TRIAL; DATA BASE; DRUG CONTRAINDICATION; EDITORIAL; FOLLOW UP; HUMAN; LOG RANK TEST; LUNG SMALL CELL CANCER; PATIENT SELECTION; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SAMPLE SIZE; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE; CONTROLLED CLINICAL TRIAL; LUNG TUMOR; METHODOLOGY; NOTE; PHASE 2 CLINICAL TRIAL; SMALL CELL CARCINOMA;

CARCINOMA, SMALL CELL; CLINICAL TRIALS, PHASE II; HUMANS; LUNG NEOPLASMS; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 33947590107     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31802c8d84     Document Type: Editorial

References (6)

1. Buchholz E, Manegold C, Pilz L, et al. Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis. J Thoracic Oncol 2007;2:51-58.
2. Burdett S, Stewart LA, Rydzewska L. A systematic review and metaanalysis of the literature: chemotherapy and surgery versus surgery alone in non-small cell lung caner. J Thoracic Oncol 2006;1:611-621.
3. Gray R, Manola J, Saxman S, et al. Phase II clinical trial design: methods in translational research from the genitourinary committee at the Eastern Cooperative Oncology Group. Clin Cancer Res 2006;12:1966-1969.
4. Rubinstein LV, Korn EL, Boris Freidlin B, Hunsberger S, Ivy SP, Smith MA. Design issues of randomized phase ii trials and a proposal for phase ii screening trials. J Clin Oncol 2005;23:7199-7206.
5. Liu PY, Moon J, LeBlanc M. Phase II selection designs. In: Crowley J, Ankerst DP (Eds.). The Handbook of Statistics in Clinical Oncology, 2nd ed. Boca Raton (FL): Chapman & Hall, 2006:155-166.
6. Francart J, Legrand C, Sylvester R, Van Glabbeke M, van Meerbeeck JP, Robert A. Progression-free survival rate as primary end point for phase ii cancer clinical trials: application to mesothelioma - The EORTC Lung Cancer Group. J Clin Oncol 2006;24:3007-3012.